Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Capital Expenditures data on record, last reported at $240000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 43.26% year-over-year to $240000.0; the TTM value through Dec 2025 reached $495000.0, down 3.13%, while the annual FY2025 figure was $495000.0, 3.13% down from the prior year.
  • Capital Expenditures reached $240000.0 in Q4 2025 per VRDN's latest filing, down from $255000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $873000.0 in Q4 2023 and bottomed at -$427000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $150277.8, with a median of $140500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: skyrocketed 4063.16% in 2022, then plummeted 430.77% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$19000.0 in 2021, then surged by 4063.16% to $753000.0 in 2022, then rose by 15.94% to $873000.0 in 2023, then tumbled by 51.55% to $423000.0 in 2024, then tumbled by 43.26% to $240000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $240000.0 in Q4 2025, $255000.0 in Q3 2025, and -$86000.0 in Q2 2025.